I am wondering if Athersys is now screwed for their COVID trial, looking at the end points selected.
Primary Outcome Measures :Ventilator-Free Days [ Time Frame: Day 0 through Day 28. ]
Safety and Tolerability as measured by the incidence of treatment-emergent adverse events as assessed by CTCAE v5.0. [ Time Frame: Day 28
]Secondary Outcome Measures :All-cause mortality [ Time Frame: Day 60 ]
Ranked hierarchical composite outcome of alive and ventilator-free [ Time Frame: Day 28 ]
Ventilator-free days [ Time Frame: Day 0 through Day 60 ]
Competition - Citius Novellus License Deal, page-4
Add MSB (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$1.09 |
Change
-0.038(3.33%) |
Mkt cap ! $1.255B | |||
| Open | High | Low | Value | Volume |
| $1.14 | $1.16 | $1.08 | $5.897M | 5.328M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 10 | 53416 | $1.09 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $1.09 | 106249 | 26 |
View Market Depth
| Last trade - 15.04pm 29/07/2024 (20 minute delay) ? |
| MSB (ASX) Chart |